Skip to content

US · USNA · HOUSEHOLD & PERSONAL PRODUCTS

USANA Health Sciences, Inc. (USNA) intrinsic value and stock valuation

$12.94as of 2026-11-21 · Mkt cap 276.76M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

USANA Health Sciences, Inc. DCF and intrinsic value

InvestorsCraft values USNA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from USNA’s statements →

USANA Health Sciences, Inc. Graham Number

Graham Number: $20.28d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Consumer Defensive · Household & Personal Products Salt Lake City, UT 84120 usana.com

How the business is doing

Fiscal 2011–2026, USD

Revenue
$925.3M-4% 5y CAGRd
20112026
Net income
$10.8M-38.7% 5y CAGRd
20112026
Free cash flow
$8.53M-43.3% 5y CAGRd
20112026
Total equity
$586.3M+5.8% 5y CAGRd
20112026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2026, USD
20262024202320222021
Revenue$925.3M$854.5M$921M$998.6M$1.19B
Operating income$50.9M$66.3M$93.1M$107.6M$170.2M
Net income$10.8M$42M$63.8M$69.4M$116.5M
EPSd$579.4K$2.19M$3.3M$3.59M$5.73M
Operating cash flow$22.4M$61M$70.6M$103.9M$121.2M
Capital expenditure-$-13.82M-$-10.07M-$-14.49M-$-10.4M-$-12.76M
Free cash flow$8.53M$50.9M$56.2M$93.5M$108.5M
Total assets$742.9M$748.2M$632.8M$596.6M$577.7M
Total debt$14M$39.2M$13.2M$13.8M$17.3M
Net debt-$-144.38M-$-142.56M-$-317.21M-$-274.64M-$-222.54M
Total equity$586.3M$586.3M$497.2M$434.5M$395.1M
Cash and short-term investments$158.4M$181.8M$330.4M$288.4M$239.8M
Income statement
20262024202320222021
Revenue$925.3M$854.5M$921M$998.6M$1.19B
Cost of revenue$200.9M$175.8M$189.4M$207.3M$230.9M
Gross profit$724.4M$678.8M$731.6M$791.3M$955.5M
Research and development expenses$0.00$11.6M$11.5M$11.6M$11.1M
Selling, general and administrative expenses$337.4M$600.9M$627.1M$672.1M$774.2M
Other expenses$336.2M$0.00$0.00$0.00$0.00
Operating expenses$673.5M$612.4M$638.5M$683.7M$785.3M
Cost and expenses$874.4M$788.2M$827.9M$891M$1.02B
Interest income$2.42M$11.3M$9.64M$3.79M$2.52M
Interest expense$840K$280K$260K$190K$60K
Depreciation and amortization$39.7M$22.2M$20.4M$21.4M$22.2M
Ebitda$82.1M$98.9M$123.1M$130.2M$192.9M
Operating income$50.9M$66.3M$93.1M$107.6M$170.2M
Total other income/expenses, net-$-9.34M$10M$9.38M$1.01M$450K
Income before tax$41.5M$76.4M$102.5M$108.6M$170.6M
Income tax expense$30.1M$34.3M$38.7M$39.3M$54.1M
Net income$10.8M$42M$63.8M$69.4M$116.5M
Weighted average shares outstanding$18.6M$19.1M$19.3M$19.3M$20.2M
Weighted average diluted shares outstanding$18.6M$19.2M$19.3M$19.3M$20.3M
Balance sheet
20262024202320222021
Cash and short-term investments$158.4M$181.8M$330.4M$288.4M$239.8M
Net receivables$0.00$8.22M$7.2M$7.21M$7.16M
Inventory$102.6M$69.7M$61.5M$67.1M$98.3M
Total current assets$288.4M$279.2M$417.8M$381.2M$362.9M
Property, plant and equipment, net$111.5M$94.6M$99.8M$117.8M$125.6M
Goodwill and intangible assets$271.1M$296M$47M$49.8M$48.1M
Long-term investments$20M$2.74M$2.83M$2.9M$23.8M
Total non-current assets$454.5M$469M$215M$215.3M$214.9M
Total assets$742.9M$748.2M$632.8M$596.6M$577.7M
Accounts payable$17.3M$12M$10.1M$11.1M$13.5M
Short-term debt$14M$29M$8.06M$6.89M$7.08M
Deferred revenue$0.00$12.1M$13.9M$20.9M$19.6M
Total current liabilities$128.6M$139.6M$118.8M$143.8M$160.8M
Long-term debt$0.00$10.2M$5.14M$6.89M$10.2M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$28.1M$22.2M$16.7M$18.2M$21.8M
Capital lease obligations$0.00$16.2M$12.4M$6.89M$10.2M
Total liabilities$156.6M$161.9M$135.6M$162.1M$182.6M
Common stock$20K$20K$20K$20K$20K
Retained earnings$465.7M$478.9M$445.2M$391.6M$344.6M
Accumulated other comprehensive income (loss)-$-16.18M-$-22.67M-$-13.7M-$-12.79M$460K
Total equity$586.3M$586.3M$497.2M$434.5M$395.1M
Total investments$20M$2.74M$2.83M$2.9M$23.8M
Total debt$14M$39.2M$13.2M$13.8M$17.3M
Net debt-$-144.38M-$-142.56M-$-317.21M-$-274.64M-$-222.54M
Cash flow statement
20262024202320222021
Net income$10.8M$42.1M$63.8M$69.4M$116.5M
Depreciation and amortization$32.6M$22.2M$20.4M$21.4M$22.2M
Stock-based compensation$13.8M$14.6M$14.6M$13.5M$14.3M
Change in working capital-$-43.08M-$-13M-$-28M$770K-$-28.86M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory-$-34.69M-$-2.12M$2.35M$15.8M-$-10.5M
Accounts payable$5.2M-$-1.27M-$-430K-$-2.66M-$-4.57M
Net cash provided by operating activities$22.4M$61M$70.6M$103.9M$121.2M
Investments in property, plant and equipment-$-13.82M-$-10.07M-$-14.49M-$-10.4M-$-12.76M
Acquisitions, net$0.00-$-203.34M$0.00-$-6.53M-$-1.94M
Net cash used for investing activities-$-10.12M-$-213.09M-$-11.97M-$-12.37M-$-14.19M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-27.51M-$-9.44M-$-11.6M-$-25.38M-$-177.84M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-40.6M$9.55M-$-14.24M-$-30.09M-$-181.41M
Net change in cash-$-23.27M-$-148.74M$41.9M$47.7M-$-72.28M
Cash at end of period$161.2M$184.5M$333.3M$291.3M$243.7M
Operating cash flow$22.4M$61M$70.6M$103.9M$121.2M
Capital expenditure-$-13.82M-$-10.07M-$-14.49M-$-10.4M-$-12.76M
Free cash flow$8.53M$50.9M$56.2M$93.5M$108.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About USANA Health Sciences, Inc.

        USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration. It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online. The company was founded in 1992 and is headquartered in Salt Lake City, Utah.

        CEO
        Kevin G. Guest
        Employees
        1.57K
        Beta
        0.73

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of USANA Health Sciences, Inc. (USNA)?

        InvestorsCraft does not currently publish an intrinsic value for USNA. How the IC value is calculated.

        Is USNA undervalued?

        InvestorsCraft does not publish an undervaluation signal for USNA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.